OmniAb, Inc. (OABIW) stock
Close on Oct 30, 2026Market cap $742.95MP/E –Yield –
OmniAb, Inc. grew revenue 90.6% to $40.21M over the twelve months to Sep 30, 2026. Free cash flow was $2.38M. At the latest close the market valued the company at $742.95M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $742.95M
- P/E ratio
- –
- Price to sales
- 18.48
- Price to book
- 2.98
- Dividend yield
- –
- Free cash flow yield
- 0.32%
Fundamentals
- Revenue
- $40.21M
- Net income
- -$43.47M
- EPS, diluted
- -$0.34
- Free cash flow
- $2.38M
- Book value per share
- $1.93
- Diluted shares
- 129M
Trading
- Next earnings
- Mar 3, 2027 (estimated, during market hours)
- Previous close
- $0.42
- Open
- $0.41
- Day's range
- $0.41 – $0.41
- Volume
- 1,380
- Average volume (20 days)
- 1,207
- Beta (5 years)
- 1.12
- 52-week range
- $1.30 – $5.43
- RSI (14 days)
- 58.7
- Volatility (1 year)
- 75.8%
- Relative volume
- 1.57×
- WACC
- 10.6%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | OABIW | S&P 500 | Difference | OABIW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.6% | -0.9% | +12.5 pts | ||
| 3 months | +391.6% | +2.1% | +389.5 pts | ||
| Year to date | +242.0% | +11.7% | +230.3 pts | ||
| 1 year | +148.5% | +12.4% | +136.1 pts | ||
| 3 years | -46.1% | +88.6% | −134.6 pts | -18.6% | +23.5% |
| 5 years | -37.9% | +75.9% | −113.8 pts | -9.1% | +12.0% |
Seven years at a glance
Fiscal years 2007 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases OmniAb filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About OmniAb
Services-Commercial Physical & Biological Research
OmniAb, Inc. creates and licenses antibody discovery technologies to pharmaceutical and biotechnology companies and academic research institutions. Its platform incorporates genetically engineered transgenic animals—including rats, mice, chickens, and cow-inspired models—to produce diverse, naturally optimized antibody repertoires with human genetic sequences. These proprietary animals are complemented by computational antigen design, microfluidic and microcapillary single B cell screening platforms, and artificial intelligence-driven bioinformatics suites for data analysis and hit optimization. Together, these technologies support the discovery of diverse therapeutic modalities such as monoclonal and bispecific antibodies, single-domain antibodies, and antibody-drug conjugates.
Company profile, executives and historyOmniAb stock: common questions
What is OmniAb's stock price?
OABIW closed at $0.41 on Oct 30, 2026, down 2.38% on the day. Over the past 52 weeks it traded between $1.30 and $5.43.
What is OmniAb's market cap?
OmniAb was worth $742.95M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is OABIW's P/E ratio?
OmniAb lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.34), so it has no meaningful P/E ratio.
How much revenue does OmniAb make?
OmniAb reported revenue of $40.21M for the twelve months to Sep 30, 2026, up 90.6% from a year earlier.
Does OmniAb pay a dividend?
No. OmniAb has not paid a cash dividend over the last twelve months.
When does OmniAb report earnings next?
OmniAb is expected to report Q4 FY2026 results on Mar 3, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has OABIW stock performed over the past year?
Including dividends, OABIW returned +148.5% over the past year, against +12.4% for the S&P 500.
Who are OmniAb's competitors?
Companies most similar to OmniAb by business, industry and size include MXCT, FOXO, ABSI, STRO, BIAF.